Terazosin

Terazosin

File:Terazosin.svg
Systematic (IUPAC) name
6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine
Pharmacokinetic data
Protein binding	90-94%
Biological half-life	12 hours
Identifiers
CAS Number	63590-64-7
ATC code	G04CA03 (WHO)
PubChem	CID 5401
DrugBank	APRD00667
Synonyms	[4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-tetrahydrofuran-2-yl-methanone
Chemical data
Formula	C19H25N5O4
Molar mass	387.433 g/mol[[]]
(verify)

Terazosin (marketed as Hytrin) is a selective alpha 1 antagonist used for treatment of symptoms of an enlarged prostate (BPH). It also acts to lower the blood pressure, and is therefore a drug of choice for men with hypertension and prostate enlargement.

It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.

Most common side effects include dizziness, drowsiness, headache, constipation, loss of appetite, fatigue, nasal congestion or dry eyes, but they generally go away after only a few days of use. Therapy should always be started with a low dose to avoid first dose phenomenon. Sexual side effects are rare, but may include priapism or erectile dysfunction.

References

de:Terazosin